Mölndal, Sweden

Anna Christina Olsson


Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Molndal, SE (2007)
  • Mölndal, SE (2008 - 2009)
  • Hovås, SE (2009)

Company Filing History:


Years Active: 2007-2009

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Anna Christina Olsson: Innovator in Pharmaceutical Science

Introduction

Anna Christina Olsson is a prominent inventor based in Mölndal, Sweden. She has made significant contributions to the field of pharmaceutical science, particularly in the development of therapeutic agents for treating lipid disorders. With a total of 4 patents to her name, her work has had a substantial impact on medical research and treatment options.

Latest Patents

Among her latest patents, Anna has developed substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR). This invention provides the S enantiomer of a compound of formula (I), wherein n is 1 or 2, along with pharmaceutically acceptable salts, solvates, crystalline forms, and prodrugs thereof. The utility of these compounds lies in their potential to treat clinical conditions, including lipid disorders (dyslipidemias), whether or not associated with insulin resistance. Additionally, she has focused on methods for their therapeutic use and pharmaceutical compositions containing them.

Career Highlights

Anna Christina Olsson is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to collaborate with other talented professionals in the field, further enhancing her contributions to pharmaceutical innovations.

Collaborations

Some of her notable coworkers include Lanna Li and Eva-Lotte Alstermark Lindstedt. Their collaborative efforts have played a crucial role in advancing research and development in their respective areas of expertise.

Conclusion

Anna Christina Olsson is a remarkable inventor whose work in pharmaceutical science continues to influence the treatment of lipid disorders. Her innovative patents and collaborations highlight her commitment to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…